Sonoma Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 8, 2024
SNOA$1.14+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
For the Nine Months ended December 31, 2023 and 2022
(In thousands, except share amounts)
| Common Stock ($0.0001 par Value) · Additional Paid in · Accumulated · Accumulated Other Comprehensive | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Loss | Total | |
| Balance, March 31, 2023 | 4,933,550 | $5 | $200,904 | $(189,514) | $(3,418) | $7,977 |
| Cost in connection with ATM | – | – | (5) | – | – | (5) |
| Employee stock-based compensation expenses | 208,046 | – | 177 | – | – | 177 |
| Foreign currency translation adjustment | – | – | – | – | 511 | 511 |
| Net loss | – | – | – | (1,418) | – | (1,418) |
| Balance, June 30, 2023 | 5,141,596 | $5 | $201,076 | $(190,932) | $(2,907) | $7,242 |
| Adjustment to correct par value | – | (4) | 4 | – | – | – |
| Employee stock-based compensation expenses | 37,737 | – | 130 | – | – | 130 |
| Foreign currency translation adjustment | – | – | – | – | (213) | (213) |
| Net loss | – | – | – | (1,484) | – | (1,484) |
| Balance, September 30, 2023 | 5,179,333 | $1 | $201,210 | $(192,416) | $(3,120) | $5,675 |
| Proceeds from October 30, 2023 offering, net of offering expenses | 8,500,000 | 1 | 1,445 | – | – | 1,446 |
| Employee stock-based compensation expenses | 5,000 | – | 140 | – | – | 140 |
| Foreign currency translation adjustment | – | – | – | – | 297 | 297 |
| Net loss | – | – | – | (866) | – | (866) |
| Balance, December 31, 2023 | 13,684,333 | $2 | $202,795 | $(193,282) | $(2,823) | $6,692 |
| Common Stock ($0.0001 par Value) · Additional Paid in · Accumulated · Accumulated Other Comprehensive | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Loss | Total | |
| Balance March 31, 2022 | 3,100,937 | $2 | $197,370 | $(184,363) | $(4,312) | $8,697 |
| Employee stock-based compensation expenses | – | – | 214 | – | – | 214 |
| Foreign currency translation adjustment | – | – | – | – | (65) | (65) |
| Net loss | – | – | – | (887) | – | (887) |
| Balance, June 30, 2022 | 3,100,937 | $2 | $197,584 | $(185,250) | $(4,377) | $7,959 |
| Employee stock-based compensation expense | – | – | 108 | – | – | 108 |
| Stock based compensation related to issuance of restricted common stock | 2,035 | – | 5 | – | – | 5 |
| Foreign currency translation adjustment | – | – | – | – | (34) | (34) |
| Net loss | – | – | – | (1,017) | – | (1,017) |
| Balance, September 30, 2022 | 3,102,972 | $2 | $197,697 | $(186,267) | $(4,411) | $7,021 |
| Employee stock-based compensation expense | – | – | 233 | – | – | 233 |
| Stock based compensation related to issuance of restricted common stock | 6,680 | – | 9 | – | – | 9 |
| Foreign currency translation adjustment | – | – | – | – | 235 | 235 |
| Net loss | – | – | – | (1,939) | – | (1,939) |
| Balance, December 31, 2022 | 3,109,652 | $2 | $197,939 | $(188,206) | $(4,176) | $5,559 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.